24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
TEMALIEVA 20 MG is an Capsule medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | TEMALIEVA 20 MG |
|---|---|
| Composition | Temozolomide Capsules IP 20mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Capsule |
| Packaging | Btl |
| Country of Origin | India |
TEMALIEVA 20 MG (Temozolomide Capsules IP 20mg) is a widely used Capsule medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
TEMALIEVA 20 MG (Temozolomide Capsules IP 20 mg) is a prescription anticancer medicine containing Temozolomide 20 mg, an oral chemotherapy agent used in the treatment of specific malignant brain tumors. Temozolomide belongs to the class of medicines known as alkylating agents, which work by damaging the DNA of cancer cells and preventing them from growing, multiplying, and spreading.
Temozolomide is widely recognized in neuro-oncology because of its unique ability to cross the blood-brain barrier, enabling it to reach and act directly on tumor cells within the brain. This characteristic makes it an important treatment option for patients with aggressive and difficult-to-treat brain cancers.
TEMALIEVA 20 MG is commonly prescribed for the treatment of Glioblastoma Multiforme (GBM), the most aggressive form of primary brain cancer, and Anaplastic Astrocytoma, a high-grade malignant brain tumor. It may be used during initial treatment, maintenance therapy, or management of recurrent disease based on the patient’s condition and oncologist’s recommendations.
The 20 mg strength is often used as part of individualized dosing regimens, allowing oncologists to accurately adjust doses according to body surface area (BSA), treatment cycles, and patient-specific requirements.
Unlike intravenous chemotherapy, TEMALIEVA 20 MG is administered orally, providing convenience and flexibility while supporting long-term cancer treatment plans.
TEMALIEVA 20 MG is commonly used for:
Manufactured according to stringent pharmaceutical quality standards, TEMALIEVA 20 MG is designed to ensure consistent quality, safety, and therapeutic effectiveness.
Patients undergoing Temozolomide treatment require regular blood count monitoring, liver function testing, and clinical evaluations to ensure safe and effective therapy.
Due to its established role in brain tumor treatment, TEMALIEVA 20 MG remains a valuable option in modern oncology and neuro-oncology care.
TEMALIEVA 20 MG (Temozolomide Capsules IP 20 mg) is primarily used in the treatment and management of malignant brain tumors.
The medicine is widely used in patients with newly diagnosed or recurrent glioblastoma.
Temozolomide is commonly prescribed for patients with anaplastic astrocytoma following surgery or radiation therapy.
The medicine forms an important part of comprehensive brain cancer treatment programs.
Doctors may recommend Temozolomide when brain tumors return after previous therapies.
The medicine may be prescribed as maintenance treatment to help control disease progression.
Temozolomide is frequently used in combination with radiation therapy.
The medicine is an integral component of modern brain cancer management.
Temozolomide belongs to a class of medicines known as Alkylating Agents.
TEMALIEVA works by:
This mechanism helps reduce the ability of cancer cells to survive and spread.
Like all medicines, TEMALIEVA 20 MG may cause side effects in some patients. The severity and frequency of side effects vary among individuals.
Nausea is one of the most frequently reported side effects.
Some patients may experience vomiting during treatment.
Weakness and tiredness are commonly reported.
Reduced appetite may affect nutritional intake.
Digestive disturbances such as constipation may occur.
Headaches may develop during therapy.
Temporary hair thinning or hair loss may occur.
Temozolomide may lower white blood cells, red blood cells, and platelet counts.
Some patients may experience dizziness during treatment.
Seek immediate medical attention if you experience:
Patients should contact their healthcare provider immediately if serious symptoms occur.
The dosage of TEMALIEVA 20 MG (Temozolomide Capsules IP 20 mg) should always be determined by a qualified oncologist.
Treatment recommendations vary according to the diagnosis.
Temozolomide dosing is typically based on body surface area calculations.
Regular monitoring helps determine dose adjustments.
Doctors may modify treatment based on effectiveness and tolerability.
Concurrent radiation therapy and other treatments may influence dosing schedules.
Before starting treatment, inform your doctor if you have:
Patients should also inform their healthcare provider about all prescription medicines, supplements, vitamins, and herbal products they are taking to avoid potential drug interactions.
Pregnant and breastfeeding women should not use this medicine unless specifically advised by a healthcare professional.
It is primarily used for the treatment of glioblastoma multiforme, anaplastic astrocytoma, and other malignant brain tumors.
Temozolomide is an oral chemotherapy medicine that damages cancer cell DNA and helps slow tumor growth.
Yes. Temozolomide is a chemotherapy medicine belonging to the alkylating agent class.
The 20 mg capsule allows oncologists to create precise, individualized dosing regimens based on patient requirements.
Yes. It can effectively reach brain tissue, making it highly useful in brain tumor treatment.
Yes. It may lower white blood cells, red blood cells, and platelet counts, requiring routine monitoring.
Yes. Blood tests, liver function monitoring, and clinical evaluations are essential throughout therapy.
Yes. This medicine should only be used under the supervision of qualified healthcare professionals experienced in oncology and neuro-oncology treatment.